Nano Dimension's $890M Infinite Epigenetics Deal Stalls as Exclusivity Expires
NNDM sits 34% above its 52-week low of $1.19 on light trading volume (0.4× avg).
Summary
Nano Dimension's proposed $890 million acquisition of Infinite Epigenetics has stalled after the exclusivity period expired without a definitive agreement. The company also appointed Nadav Kidron to its board.
Key Events · M&A and Partnerships · NNDM
-
Infinite Epigenetics Deal Stalls
The 30-day exclusivity period under the non-binding term sheet expired on July 15, 2026, and as of August 16, 2026, no definitive agreement has been reached.
-
Strategic Pivot in Limbo
The $890 million acquisition was central to Nano Dimension's pivot into epigenetics and its defense against activist Murchinson; its stall leaves the company's direction uncertain.
-
New Director Appointed
Nadav Kidron, CEO of Oramed Pharmaceuticals, was appointed to the board as a Class II director, effective immediately, and will serve on the Audit and Compensation Committees.
-
Next Milestone Unclear
The filing does not state whether negotiations will continue or if the company will pursue alternative strategies.
Analysis · NNDM · Manufacturing
The non-binding term sheet to acquire Infinite Epigenetics for $890 million has lapsed without a definitive agreement. The 30-day exclusivity period ended July 15, 2026, and as of August 16, 2026, no deal has been reached. This is a material setback for the company's strategic pivot, which was announced in June 2026 and was a central element of its defense against activist investor Murchinson. The appointment of Nadav Kidron, an experienced life sciences executive, to the board may signal a continued focus on the healthcare sector, but the stalled acquisition leaves the company's strategic direction uncertain.
How filings like this one have moved
In the 30 days to Oct 2, 2026, 29.6% of the 1645 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.57%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, NNDM was trading at $1.59 on NASDAQ in the Manufacturing sector, with a market capitalization of approximately $334.8M. The 52-week trading range was $1.19 to $2.32. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.